Status:
ENROLLING_BY_INVITATION
Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
Dermavant Sciences, Inc.
Conditions:
ICD10 Code L40.9 for Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this prospective study is to evaluate the degree of post-inflammatory pigmentation alteration on legs of study subjects treated with two different psoriasis treatments. Betamethasone di...
Detailed Description
Subjects will be randomized to either of the two treatment groups (betamethasone dipropionate or tapinarof) and will be treated with that medication for until clear or up to 12 weeks . Photographs wil...
Eligibility Criteria
Inclusion
- Adults (age 18+) with Fitzpatrick skin type 3 or higher who have been diagnosed with ICD10 code L40.9 for psoriasis between \[dates\] at Atrium Health Wake Forest Baptist Medical Center.
- Stable on other therapies such as biologics for at least 3 months before randomization.
Exclusion
- Lack of a diagnosis of psoriasis (ICD10 code L40.9) or Fitzpatrick skin type below 3.
- Pigmentary changes that in the opinion of the investigator would compromise the ability to assess the study outcomes.
Key Trial Info
Start Date :
July 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05981118
Start Date
July 15 2024
End Date
December 1 2026
Last Update
December 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Health Sciences Department of Dermatology
Winston-Salem, North Carolina, United States, 27157